je.st
news
Tag: litigation
Arlington and Bridgeport Settle All Currently Pending Litigation
2017-10-19 11:00:00| Electrical Construction & Maintenance
As part of the settlement, Arlington received an additional $1.37 million for the judgment in case No. 3:06-cv-1105 in the Middle District of Pennsylvania against Bridgeports 3838ASP and 3838SP Whipper-Snap Duplex connectors.
Tags: pending
litigation
arlington
settle
Environmental Groups File Litigation Regarding Chiquita Canyon Landfill Expansion Approval
2017-08-31 16:12:39| Waste Age
The groups' paperwork cites concerns with the landfills effect on air quality, climate change, health, proximity to schools and the impact on minority and/or low-income populations.
Tags: file
groups
environmental
approval
AMD Agrees to Pay $29.5 Million to Settle Fusion APU Litigation
2017-08-30 19:01:41| Extremetech
AMD has agreed to settle a lawsuit about the timing and communication of its Llano processor launch by paying $29.5M. The company did not admit wrongdoing. The post AMD Agrees to Pay $29.5 Million to Settle Fusion APU Litigation appeared first on ExtremeTech.
Milpitas, Calif., Opts to Continue Litigation Over Landfill Expansion Decision
2017-06-16 20:32:00| Waste Age
The Milpitas City Council voted to continue litigation against the California Department of Resources Recycling and Recovery for not considering odor complaints in approving a landfill expansion.
Tags: continue
decision
expansion
litigation
Merck Announces Settlement and License Agreement Resolving KEYTRUDA (pembrolizumab) Patent Litigation
2017-01-20 22:01:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada), and certain of its affiliates, today announced it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., resolving the worldwide patent infringement litigation related to the use of an anti-PD-1 antibody for the treatment of cancer, such as KEYTRUDA (pembrolizumab). Language: English Contact: Merck Media: Pamela Eisele, 267-305-3558Claire Gillespie, 267-305-0932or Investors: Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: agreement
license
patent
settlement
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] next »